nach oben

vorheriger Artikel Homologous recombination deficiency in breast c...

nächster Artikel Transoral robotic surgery in head and neck cancer

Tipp

Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 4/2020

Autor:: Bernhard Doleschal

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Molecular targeted therapies in pancreatic ductal adenocarcinoma (PDAC) lag behind treatment options in other tumor entities. The POLO trial has provided promising preliminary data for targeting gBRCA in PDAC by the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib. This review tries to show further potential approaches to exploit faulty DNA repair mechanisms beyond gBRCA and olaparib.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Jetzt informieren

Statistik Austria. Krebserkrankungen in Österreich 2020. 2020.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. CrossRef

Hoff DDV, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. CrossRef

Wang-Gillam A, Hubner RA, Siveke JT, Hoff DDV, Belanger B, de Jong FA, et al. NAPOLI‑1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87. CrossRef

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 2007;25(15):1960–6. CrossRef

Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers. 2017;9(12):42. CrossRef

Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5(4):387–93. CrossRef

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, et al. Genomic methods identify homologous recombination deficiency in pancreas Adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239–47.

Golan T, Hammel P, Reni M, Cutsem EV, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27. CrossRef

10.

Dahan L, Phelip JM, Malicot KL, Williet N, Desrame J, Volet J, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). J Clin Oncol. 2018;36(15_suppl):4000. CrossRef

11.

Bangee EM, et al. Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma. JCO Oncol Pract. 2020;16:e678–e87. CrossRef

12.

Binder KAR, Mick R, O’Hara M, Teitelbaum U, Karasic T, Schneider C, et al. Abstract CT234: A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2. 2019. pp. CT234–CT234.

13.

Kasi A, Chalise P, Williamson SK, Baranda JC, Sun W, Al-Rajabi RMT, et al. Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): a phase 2 trial. J Clin Oncol. 2019;37(15_suppl):TPS4168–TPS4168. CrossRef

14.

Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2014;33(3):244–50. CrossRef

15.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol. 2018;2018(2):1–15.

16.

Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497–509. CrossRef

17.

O’Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of Gemcitabine and Cisplatin with or without Veliparib in patients with pancreas Adenocarcinoma and a Germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38(13):1378–88. CrossRef

18.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of Gemcitabine plus Cisplatin compared with Gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946–52. CrossRef

19.

Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, et al. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2‑mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev. 2019;80:101895. CrossRef

20.

Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw. 2019;17(5.5):603–5. PubMed

21.

Mosele F, et al. Recommendations for the use of next generation sequencing (NGS) for patient with metastatic cancers: A report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;S0923-7534(20)39971-3.

Titel: Tackling DNA damage repair mechanisms—a promising molecular informed therapeutic approach in pancreatic ductal adenocarcinoma
Autor:: Bernhard Doleschal
Publikationsdatum: 21.10.2020
DOI: https://doi.org/10.1007/s12254-020-00658-1
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Publisher’s Note

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 4/2020

Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC)

Homologous recombination deficiency: New biomarkers in innovative treatments

Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer

Systemic therapy for metastatic salivary gland tumors—challenges and novel concepts

Ovarian transposition

Fertility preservation procedures in girls, adolescents and women